- Home
- SPOK vs RCEL Comparison
SPOK vs RCEL Comparison
Compare SPOK & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- RCEL
- Stock Information
- Founded
- SPOK 2004
- RCEL 2020
- Country
- SPOK United States
- RCEL United States
- Employees
- SPOK N/A
- RCEL N/A
- Industry
- SPOK Telecommunications Equipment
- RCEL Medical/Dental Instruments
- Sector
- SPOK Telecommunications
- RCEL Health Care
- Exchange
- SPOK Nasdaq
- RCEL Nasdaq
- Market Cap
- SPOK 315.5M
- RCEL 310.6M
- IPO Year
- SPOK 1992
- RCEL N/A
- Fundamental
- Price
- SPOK $16.54
- RCEL $11.95
- Analyst Decision
- SPOK Hold
- RCEL Hold
- Analyst Count
- SPOK 1
- RCEL 3
- Target Price
- SPOK $15.00
- RCEL $16.50
- AVG Volume (30 Days)
- SPOK 121.8K
- RCEL 99.4K
- Earning Date
- SPOK 10-30-2024
- RCEL 11-07-2024
- Dividend Yield
- SPOK 7.56%
- RCEL N/A
- EPS Growth
- SPOK N/A
- RCEL N/A
- EPS
- SPOK 0.71
- RCEL N/A
- Revenue
- SPOK $137,714,000.00
- RCEL $60,040,000.00
- Revenue This Year
- SPOK $2.45
- RCEL $34.73
- Revenue Next Year
- SPOK $0.80
- RCEL $54.61
- P/E Ratio
- SPOK $23.29
- RCEL N/A
- Revenue Growth
- SPOK N/A
- RCEL 32.24
- 52 Week Low
- SPOK $13.24
- RCEL $7.51
- 52 Week High
- SPOK $18.14
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- SPOK 63.80
- RCEL 57.86
- Support Level
- SPOK $16.52
- RCEL $11.16
- Resistance Level
- SPOK $16.25
- RCEL $13.37
- Average True Range (ATR)
- SPOK 0.41
- RCEL 0.72
- MACD
- SPOK 0.08
- RCEL 0.12
- Stochastic Oscillator
- SPOK 72.12
- RCEL 57.23
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.